9 results on '"Yang, Dong"'
Search Results
2. Detection of pancreatic cancer with two- and three-dimensional radiomic analysis in a nationwide population-based real-world dataset
- Author
-
Chang, Dawei, Chen, Po-Ting, Wang, Pochuan, Wu, Tinghui, Yeh, Andre Yanchen, Lee, Po-Chang, Sung, Yi-Hui, Liu, Kao-Lang, Wu, Ming-Shiang, Yang, Dong, Roth, Holger, Liao, Wei-Chih, and Wang, Weichung
- Published
- 2023
- Full Text
- View/download PDF
3. Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis
- Author
-
Li, Zhiru, Li, Chao, Yang, Dong, Song, Junmei, Liu, Ting, Zhou, Ziyan, Zhou, Lifang, and Kang, Min
- Published
- 2022
- Full Text
- View/download PDF
4. Identification of a protein signature for predicting overall survival of hepatocellular carcinoma: a study based on data mining
- Author
-
Wu, Zeng-hong and Yang, Dong-liang
- Published
- 2020
- Full Text
- View/download PDF
5. Identification of C3 and FN1 as potential biomarkers associated with progression and prognosis for clear cell renal cell carcinoma
- Author
-
Tao Fan, Tian Xia, Chun-hui Hu, Wen Yang, Yang Dong, Shao-qi Zhang, Wen-da Zhang, Lin Hao, Cong-hui Han, Kun Fang, Zhen-duo Shi, Wei-ming Ma, and Qianjin Zhang
- Subjects
Clear cell renal cell carcinoma ,Cancer Research ,Candidate gene ,medicine.medical_treatment ,Human Protein Atlas ,Biology ,Complement component 3 ,medicine.disease_cause ,Targeted therapy ,Gene expression ,Biomarkers, Tumor ,Genetics ,medicine ,Humans ,Carcinoma, Renal Cell ,Gene ,RC254-282 ,Competing endogenous RNA ,Research ,Fibronectin 1 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Biomarker ,medicine.disease ,Survival Analysis ,Kidney Neoplasms ,Fibronectins ,Oncology ,Disease Progression ,Cancer research ,Carcinogenesis ,Prognostic value - Abstract
Background Clear cell renal cell carcinoma (ccRCC) is one of the most lethal urological malignancies, but the pathogenesis and prognosis of ccRCC remain obscure, which need to be better understand. Methods Differentially expressed genes were identified and function enrichment analyses were performed using three publicly available ccRCC gene expression profiles downloaded from the Gene Expression Omnibus database. The protein-protein interaction and the competing endogenous RNA (ceRNA) networks were visualized by Cytoscape. Multivariate Cox analysis was used to predict an optimal risk mode, and the survival analysis was performed with the Kaplan-Meier curve and log-rank test. Protein expression data were downloaded from Clinical Proteomic Tumor Analysis Consortium database and Human Protein Atlas database, and the clinical information as well as the corresponding lncRNA and miRNA expression data were obtained via The Cancer Genome Atlas database. The co-expressed genes and potential function of candidate genes were explored using data exacted from the Cancer Cell Line Encyclopedia database. Results Of the 1044 differentially expressed genes shared across the three datasets, 461 were upregulated, and 583 were downregulated, which significantly enriched in multiple immunoregulatory-related biological process and tumor-associated pathways, such as HIF-1, PI3K-AKT, P53 and Rap1 signaling pathways. In the most significant module, 36 hub genes were identified and were predominantly enriched in inflammatory response and immune and biotic stimulus pathways. Survival analysis and validation of the hub genes at the mRNA and protein expression levels suggested that these genes, particularly complement component 3 (C3) and fibronectin 1 (FN1), were primarily responsible for ccRCC tumorigenesis and progression. Increased expression of C3 or FN1 was also associated with advanced clinical stage, high pathological grade, and poor survival in patients with ccRCC. Univariate and multivariate Cox regression analysis qualified the expression levels of the two genes as candidate biomarkers for predicting poor survival. FN1 was potentially regulated by miR-429, miR-216b and miR-217, and constructed a bridge to C3 and C3AR1 in the ceRNA network, indicating a critical position of FN1. Conclusions The biomarkers C3 and FN1 could provide theoretical support for the development of a novel prognostic tool to advance ccRCC diagnosis and targeted therapy.
- Published
- 2021
6. The ERH gene regulates migration and invasion in 5637 and T24 bladder cancer cells
- Author
-
Lin Hao, Han Xiaoxiao, Guang-hui Zang, Jie Wang, Jianjun Zhang, Zhiguo Zhang, Kun Pang, Longjun Cai, Rui Li, Bo Chen, Zhen-duo Shi, Conghui Han, Ying Liu, and Yang Dong
- Subjects
0301 basic medicine ,Cancer Research ,Cell ,Mice, Nude ,Cell Cycle Proteins ,urologic and male genital diseases ,lcsh:RC254-282 ,Small hairpin RNA ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Nude mouse ,ERH gene ,Cell Movement ,Cell Line, Tumor ,Gene expression ,Genetics ,medicine ,Animals ,Humans ,Neoplasm Invasiveness ,Migration and invasion ,Gene knockdown ,Migration Assay ,biology ,Chemistry ,Gene Expression Profiling ,Bladder cancer ,Cell migration ,biology.organism_classification ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Gene expression profiling ,030104 developmental biology ,medicine.anatomical_structure ,Urinary Bladder Neoplasms ,Oncology ,Gene Knockdown Techniques ,030220 oncology & carcinogenesis ,Cancer research ,MYC gene ,Research Article ,Transcription Factors - Abstract
Background This study aimed to determine whether the enhancer of the rudimentary homolog (ERH) gene regulates cell migration and invasion in human bladder urothelial carcinoma (BUC) T24 cells and the underlying mechanism. Methods First, we knocked down ERH in BUC T24 and 5637 cells by shRNA and then used wound healing cell scratch migration assays, transwell cell migration assays, transwell cell invasion chamber experiments and nude mouse tail vein transfer assays to determine the migration and invasion ability after ERH was knocked down. Moreover, we used gene expression profiling chip analysis and further functional experiments to explore the possible mechanism through which ERH knockdown downregulated metastasis ability in T24 cells. Results Wound healing cell scratch migration assays, transwell cell migration assays, transwell cell invasion chamber experiments and nude mouse tail vein transfer assays all showed that the metastasis ability was significantly inhibited in human BUC T24 and 5637 cells with ERH knockdown. A gene expression profiling chip analysis in T24 cells showed that the MYC gene may be an important downstream target of the ERH gene, and the functional experiments showed that MYC is a functional target of ERH in BUC T24 cells. Conclusion ERH knockdown could inhibit the metastasis of BUC T24 cells in vitro and in vivo. This study further explored the mechanism of the ERH gene in the metastasis of the T24 human bladder cancer cell line and found that ERH may regulate MYC gene expression. The results of this research provide a basis for the clinical application of ERH as a potential target for BUC treatment. Electronic supplementary material The online version of this article (10.1186/s12885-019-5423-9) contains supplementary material, which is available to authorized users.
- Published
- 2019
7. Metabolic syndrome score as an indicator in a predictive nomogram for lymph node metastasis in endometrial cancer
- Author
-
Xuan Feng, Xing Chen Li, Xiao Yang, Yuan Cheng, Yang Yang Dong, Jing Yuan Wang, Jing Yi Zhou, and Jian Liu Wang
- Subjects
Endometrial cancer ,Metabolic ,Lymph node metastasis ,Nomogram ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Lymph node metastasis (LNM) is an important factor affecting endometrial cancer (EC) prognosis. Current controversy exists as to how to accurately assess the risk of lymphatic metastasis. Metabolic syndrome has been considered a risk factor for endometrial cancer, yet its effect on LNM remains elusive. We developed a nomogram integrating metabolic syndrome indicators with other crucial variables to predict lymph node metastasis in endometrial cancer. Methods This study is based on patients diagnosed with EC in Peking University People’s Hospital between January 2004 and December 2020. A total of 1076 patients diagnosed with EC and who underwent staging surgery were divided into training and validation cohorts according to the ratio of 2:1. Univariate and multivariate logistic regression analyses were used to determine the significant predictive factors. Results The prediction nomogram included MSR, positive peritoneal cytology, lymph vascular space invasion, endometrioid histological type, tumor size > = 2 cm, myometrial invasion > = 50%, cervical stromal invasion, and tumor grade. In the training group, the area under the curve (AUC) of the nomogram and Mayo criteria were 0.85 (95% CI: 0.81–0.90) and 0.77 (95% CI: 0.77–0.83), respectively (P
- Published
- 2023
- Full Text
- View/download PDF
8. Identification of C3 and FN1 as potential biomarkers associated with progression and prognosis for clear cell renal cell carcinoma
- Author
-
Yang Dong, Wei-ming Ma, Wen Yang, Lin Hao, Shao-qi Zhang, Kun Fang, Chun-hui Hu, Qian-jin Zhang, Zhen-duo Shi, Wen-da Zhang, Tao Fan, Tian Xia, and Cong-hui Han
- Subjects
Clear cell renal cell carcinoma ,Biomarker ,Prognostic value ,Complement component 3 ,Fibronectin 1 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Clear cell renal cell carcinoma (ccRCC) is one of the most lethal urological malignancies, but the pathogenesis and prognosis of ccRCC remain obscure, which need to be better understand. Methods Differentially expressed genes were identified and function enrichment analyses were performed using three publicly available ccRCC gene expression profiles downloaded from the Gene Expression Omnibus database. The protein-protein interaction and the competing endogenous RNA (ceRNA) networks were visualized by Cytoscape. Multivariate Cox analysis was used to predict an optimal risk mode, and the survival analysis was performed with the Kaplan-Meier curve and log-rank test. Protein expression data were downloaded from Clinical Proteomic Tumor Analysis Consortium database and Human Protein Atlas database, and the clinical information as well as the corresponding lncRNA and miRNA expression data were obtained via The Cancer Genome Atlas database. The co-expressed genes and potential function of candidate genes were explored using data exacted from the Cancer Cell Line Encyclopedia database. Results Of the 1044 differentially expressed genes shared across the three datasets, 461 were upregulated, and 583 were downregulated, which significantly enriched in multiple immunoregulatory-related biological process and tumor-associated pathways, such as HIF-1, PI3K-AKT, P53 and Rap1 signaling pathways. In the most significant module, 36 hub genes were identified and were predominantly enriched in inflammatory response and immune and biotic stimulus pathways. Survival analysis and validation of the hub genes at the mRNA and protein expression levels suggested that these genes, particularly complement component 3 (C3) and fibronectin 1 (FN1), were primarily responsible for ccRCC tumorigenesis and progression. Increased expression of C3 or FN1 was also associated with advanced clinical stage, high pathological grade, and poor survival in patients with ccRCC. Univariate and multivariate Cox regression analysis qualified the expression levels of the two genes as candidate biomarkers for predicting poor survival. FN1 was potentially regulated by miR-429, miR-216b and miR-217, and constructed a bridge to C3 and C3AR1 in the ceRNA network, indicating a critical position of FN1. Conclusions The biomarkers C3 and FN1 could provide theoretical support for the development of a novel prognostic tool to advance ccRCC diagnosis and targeted therapy.
- Published
- 2021
- Full Text
- View/download PDF
9. The ERH gene regulates migration and invasion in 5637 and T24 bladder cancer cells
- Author
-
Kun Pang, Zhiguo Zhang, Lin Hao, Zhenduo Shi, Bo Chen, Guanghui Zang, Yang Dong, Rui Li, Ying Liu, Jie Wang, Jianjun Zhang, Longjun Cai, Xiaoxiao Han, and Conghui Han
- Subjects
ERH gene ,Bladder cancer ,MYC gene ,Migration and invasion ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background This study aimed to determine whether the enhancer of the rudimentary homolog (ERH) gene regulates cell migration and invasion in human bladder urothelial carcinoma (BUC) T24 cells and the underlying mechanism. Methods First, we knocked down ERH in BUC T24 and 5637 cells by shRNA and then used wound healing cell scratch migration assays, transwell cell migration assays, transwell cell invasion chamber experiments and nude mouse tail vein transfer assays to determine the migration and invasion ability after ERH was knocked down. Moreover, we used gene expression profiling chip analysis and further functional experiments to explore the possible mechanism through which ERH knockdown downregulated metastasis ability in T24 cells. Results Wound healing cell scratch migration assays, transwell cell migration assays, transwell cell invasion chamber experiments and nude mouse tail vein transfer assays all showed that the metastasis ability was significantly inhibited in human BUC T24 and 5637 cells with ERH knockdown. A gene expression profiling chip analysis in T24 cells showed that the MYC gene may be an important downstream target of the ERH gene, and the functional experiments showed that MYC is a functional target of ERH in BUC T24 cells. Conclusion ERH knockdown could inhibit the metastasis of BUC T24 cells in vitro and in vivo. This study further explored the mechanism of the ERH gene in the metastasis of the T24 human bladder cancer cell line and found that ERH may regulate MYC gene expression. The results of this research provide a basis for the clinical application of ERH as a potential target for BUC treatment.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.